Tests recommended one to three days before the flight, three to five days after the flight, and one to three days before returning
CDC’s Vaccine Committee Prepares COVID-19 Vaccine Allocations
The Advisory Committee on Immunization Practices (ACIP) held an out-of-schedule, emergency meeting to discuss various issues related to experimental COVID-19 vaccine candidates.
Held at the US Centers for Disease Control and Prevention (CDC)’s Atlanta, Georgia Healthquarters, this digital meeting was opened by the Director Dr. Robert R. Redfield on November 23, 2020.
Oxford University’s COVID-19 Vaccine Found Very Effective
The University of Oxford and its vaccine production partner AstraZeneca announced positive high-level results from an initial analysis of clinical trials of the experimental vaccine candidate, AZD1222.
Chimpanzee Adenovirus COVID-19 Vaccine Promising in Seniors
Immunogenicity similar across age groups; vaccine better tolerated in older versus younger adults
WHO: Remdesivir Not Advised for Hospitalized COVID-19 Patients
Evidence to date has not shown clinically important effects on mortality, need for mechanical ventilation
Third COVID-19 Vaccine Shows Effectiveness
The AstraZeneca vaccine becomes the third to show good effectiveness
AHA Meeting Addresses Latest Research, COVID-19, Health Care Disparities
American Heart Association President-Elect Donald Lloyd-Jones, M.D., discussed highlights of the AHA Scientific Sessions 2020 with HD Live!
FDA Authorizes Use of Monoclonal Antibody Treatment for COVID-19
IV infusion of casirivimab and imdevimab authorized for treatment of mild-to-moderate COVID-19
New Polio Vaccine Recommendation Issued
The World Health Organization’s (WHO) Prequalification program issued an Emergency Use Listing (EUL) recommendation for the type 2 novel oral polio vaccine (nOPV2).
This announcement on November 13, 2020, will enable the rollout of the nOPV2 vaccine for use in countries affected by circulating vaccine-derived poliovirus type 2 (cVDPV2) outbreaks.
The WHO stated: ‘clinical trials of the new vaccine have shown it to be safe and provide comparable protection against polio, as the currently used type 2 monovalent OPV (mOPV2) vaccine.